Sunshine Biopharma discloses lower exercise price on Series B warrants
The company said stock sales under its at-the-market offering triggered an anti-dilution adjustment, cutting the Series B Warrant exercise price to $1.2046.
Sunshine Biopharma Inc. filed an 8-K dated September 11, 2026, disclosing a change to its outstanding Series B Warrants.
The company said that because of recent sales of its common stock through its previously disclosed at-the-market offering, the Series B Warrants' exercise price now stands at $1.2046, a figure that remains open to further adjustment under the warrants' terms.1
The filing was submitted under Item 8.01, Other Events, and does not provide additional detail on the size of the at-the-market sales that triggered the adjustment or the prior exercise price of the warrants.
Sunshine Biopharma is incorporated in Colorado and trades on The Nasdaq Stock Market LLC under the ticker symbols SBFM for its common stock and SBFMW for its common stock purchase warrants. The company is based in Fort Lauderdale, Florida.
The report was signed by Dr. Steve N. Slilaty, the company's Chief Executive Officer.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.